PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. (PMVP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pmvp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for PMV Pharmaceuticals, Inc. (PMVP) measures how much investors pay for each dollar of the company's trailing earnings. PMVP's current PE ratio of N/A is calculated by dividing its stock price of $1.09 by its TTM earnings per share of -$1.47.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PMV Pharmaceuticals, Inc.You PMVP | $58M | N/A | — | -$1.47 |
 Acrivon Therapeutics, Inc. Common Stock ACRV | $44M | N/A | — | -$2.02 |
 aTyr Pharma, Inc. ATYR | $43M | N/A | — | -$0.80 |
 Biomea Fusion, Inc. BMEA | $68M | N/A | — | -$1.18 |
 Cibus, Inc. CBUS | $56M | N/A | — | -$0.28 |
 Immunic, Inc. IMUX | $119M | N/A | — | -$6.24 |
 Lite Strategy, Inc. LITS | $26M | N/A | — | -$2.39 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.48 | — | |
2024-12-31 FY2024 | — | $-1.14 | — | |
2023-12-31 FY2023 | — | $-1.44 | — | |
2022-12-31 FY2022 | — | $-1.61 | — | |
2021-12-31 FY2021 | — | $-1.28 | — | |
2020-12-31 FY2020 | — | $-0.77 | — | |
2019-12-31 FY2019 | — | $-0.59 | — | |
2018-12-31 FY2018 | — | $-5.80 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PMV Pharmaceuticals, Inc. (PMVP) measures how much investors pay for each dollar of the company's trailing earnings. PMVP's current PE ratio of N/A is calculated by dividing its stock price of $1.09 by its TTM earnings per share of -$1.47.
Frequently asked questions
PMVP pe ratio · 6 questionsPMVP's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.09 and TTM EPS of -$1.47. Data sourced from Financial Modeling Prep via PMVP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PMV Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09